Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKH8PF)

Drug Name

H-[Trp-Arg-Nva-Arg-Tyr]3-NH2 Drug Info

Synonyms

CHEMBL413871; H-[Trp-Arg-Nva-Arg-Tyr]3-NH2

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 44409453
TTD Drug ID: DMKH8PF

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Neuropeptide Y receptor type 2 (NPY2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NEUROPEPTIDE-Y	DMINQP1	N. A.	N. A.	Phase 2	[2]
TM30338	DMXNQLU	Obesity	5B81	Discontinued in Phase 2	[3]
PYY3-36	DMTGFV6	Obesity	5B81	Discontinued in Phase 2	[4]
AC-162352	DME98LV	Obesity	5B81	Discontinued in Phase 1	[4]
BMS-192548	DMHAWBR	Obesity	5B81	Preclinical	[4]
CIN-110	DMYMZQW	Obesity	5B81	Preclinical	[5]
Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DM4SWQA	Discovery agent	N.A.	Investigative	[1]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DMBERSG	Discovery agent	N.A.	Investigative	[1]
Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2	DM56MOV	Discovery agent	N.A.	Investigative	[1]
H-[Trp-Arg-Nva-Arg-Tyr]2-NH2	DM9XK05	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Neuropeptide Y receptor type 4 (NPY4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TM30338	DMXNQLU	Obesity	5B81	Discontinued in Phase 2	[3]
TM30339	DMW7LQT	Schizophrenia	6A20	Discontinued in Phase 2	[6]
Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DM4SWQA	Discovery agent	N.A.	Investigative	[1]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DMBERSG	Discovery agent	N.A.	Investigative	[1]
Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2	DM56MOV	Discovery agent	N.A.	Investigative	[1]
H-[Trp-Arg-Nva-Arg-Tyr]2-NH2	DM9XK05	Discovery agent	N.A.	Investigative	[1]
Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DMVWM75	Discovery agent	N.A.	Investigative	[1]
[Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2	DMWFGBC	Discovery agent	N.A.	Investigative	[1]
[125I]GR231118	DMFWE4H	Discovery agent	N.A.	Investigative	[7]
PD-4074	DM4BDEY	Diabetic complication	5A2Y	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Neuropeptide Y receptor type 1 (NPY1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NEUROPEPTIDE-Y	DMINQP1	N. A.	N. A.	Phase 2	[9]
H-409/22	DMYJ9CF	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[10]
PD-160170	DMB9Z4C	Heart disease	BA41-BA42	Preclinical	[4]
GI-264879A	DM25N8B	Obesity	5B81	Preclinical	[4]
SR 120819A	DMETDFM	Eating disorder	6B82	Terminated	[11]
BIBP 3226	DMYBR9D	Hypertension	BA00-BA04	Terminated	[12]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[13]
Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DM4SWQA	Discovery agent	N.A.	Investigative	[1]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DMBERSG	Discovery agent	N.A.	Investigative	[1]
Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2	DM56MOV	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neuropeptide Y receptor type 1 (NPY1R)	TTRK9JT	NPY1R_HUMAN	Inhibitor	[1]
Neuropeptide Y receptor type 2 (NPY2R)	TTJ6WK9	NPY2R_HUMAN	Inhibitor	[1]
Neuropeptide Y receptor type 4 (NPY4R)	TTW4N16	NPY4R_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
2	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
3	Anti-Obesity Drug Discovery and Development, Atta-ur- Rahman, page(108)
4	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
5	Clinical pipeline report, company report or official report of CinFina Pharma
6	Neuropeptide y receptor selective ligands in the treatment of obesity. Endocr Rev. 2007 Oct;28(6):664-84.
7	[(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors. Br J Pharmacol. 2000 Jan;129(1):37-46.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 307).
9	5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6.
10	In vivo characterization of the novel neuropeptide Y Y1 receptor antagonist H 409/22. J Cardiovasc Pharmacol. 2000 Oct;36(4):516-25.
11	SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett. 1995 Apr 3;362(2):192-6.
12	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 305).
13	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.